A urokinase-derived peptide (Å6) increases survival of mice bearing orthotopically grown prostate cancer and reduces lymph node metastasis

American Journal of Pathology

Volumn 162, Issue 2, 2003, Pages 619-626

  Boyd, Douglas D ^a   Kim, Sun Jin ^a   Wang, Heng ^a   Jones, Terence R ^b   Gallick, Gary E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Angstrom Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLLYSYLPROLYLSERYLSERYLPROLYLPROLYLGLUTAMYLGLUTAMINAMIDE; GROWTH FACTOR; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG; UROKINASE; UROKINASE RECEPTOR; CELL SURFACE RECEPTOR; ENZYME PRECURSOR; MESSENGER RNA; PEPTIDE FRAGMENT; PLASMINOGEN ACTIVATOR, UROKINASE RECEPTORS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CONTROL; CANCER GROWTH; CANCER INVASION; CANCER MODEL; CANCER MORTALITY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; EXTRACELLULAR MATRIX; LYMPH NODE METASTASIS; MALE; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; ANIMAL; CHEMISTRY; GENETICS; MORTALITY; PATHOLOGY; PROSTATE TUMOR;

ANIMALS; ENZYME PRECURSORS; LYMPHATIC METASTASIS; MALE; MICE; NEOPLASM INVASIVENESS; PEPTIDE FRAGMENTS; PROSTATIC NEOPLASMS; RECEPTORS, CELL SURFACE; RNA, MESSENGER; URINARY PLASMINOGEN ACTIVATOR;

EID: 0037289755     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)63855-2     Document Type: Article

References (34)

1. Naldini L, Tamagnone L, Vigna E, Sachs M, Hartmann G, Birchmeier W, Daikuhara Y, Tsubouchi H, Blasi F, Comoglio PM: Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth/scatter factor. Eur Mol Biol Org 1992, 11:4825-4833
2. Wun T, Ossowski L, Reich E: A proenzyme form of human urokinase. J Biol Chem 1982, 257:7262-7268
3. Liotta L, Goldfarb R, Brundage R, Siegel G, Terranova V, Garbisa S: Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane. Cancer Res 1981, 41:4629-4636
4. Ginestra A, Monea S, Seghezzi G, Dolo V, Nagase H, Mignatti P, Vittorelli M: Urokinase plasminogen activator and gelatinases are associated with membrane vesicles shed by human HT1080 cells. J Biol Chem 1997, 272:17216-17222
5. Mackay AR, Corbitt RH, Hartzler JL, Thorgeirsson UP: Basement membrane type IV collagen degradation: evidence for the involvement of a proteolytic cascade independent of metalloproteinases. Cancer Res 1990, 50:5997-6001
6. Nielsen L, Kellerman GM, Behrendt N, Picone R, Dano K, Blasi F: A 55,000-60,000 Mr receptor protein for urokinase-type plasminogen activator. J Biol Chem 1988, 263:2358-2363
7. Ellis V. Behrendt N, Dano K: Plasminogen activation by receptor-bound urokinase. J Biol Chem 1991, 266:12752-12758
8. Resnati M, Pallavicini I, Wang JM, Oppenheim J, Serhan CN, Romano M, Blasi F: The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactin receptor FPRL1/LXA4R. Proc Natl Acad Sci USA 2002, 99:1359-1364
9. Yebra M, Parry GCN, Stromblad S, Mackman N, Rosenberg S, Mueller BM, Cheresh DA: Requirement of receptor-bound urokinase-type plasminogen activator for integrin α νβ5-directed cell migration. J Biol Chem 1996, 271:29393-29399
10. Helenius MA, Saramaki OR, Linja MJ, Tammela TLJ, Visakorpi T: Amplification of urokinase gene in prostate cancer. Cancer Res 2001, 61:5340-5344
11. Achbarou A, Kaiser S, Tremblay G, Ste-Marie L, Brodt P, Goltzman D, Rabbani SA: Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Res 1994, 54:2372-2377
12. Crowley CW, Cohen R, Lucas BK, Liu G, Shuman MA, Levinson AD: Prevention of metastasis by inhibition of the urokinase receptor. Proc Natl Acad Sci USA 1993, 90:5021-5025
13. Evans CP, Elfman F, Parangi S, Conn M, Cunha G, Shuman M: Inhibition of prostate cancer neovascularization and growth by urokinase-plasminogen activator receptor blockade. Cancer Res 1997, 57:3594-3599
14. Festuccia C, Dolo V, Guerra F, Violini S, Muzi P, Pavan A, Bologna M: Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells. Clin Exp Metast 1998, 16:513-528
15. Hollas W, Hoosein N, Chung LWK, Mazar A, Henkin J, Kariko K, Barnathan E, Boyd D: Expression of urokinase and its receptor in invasive and non-invasive prostate cancer cell lines. Thromb Haemost 1992, 68:662-666
16. Miyake H, Hara I, Yamanaka K, Gohji K, Arakawa S, Kamidono S: Elevation of serum levels of urokinase-type plasminogen and its receptor is associated with disease progression and prognosis in patients with prostate cancer. Prostate 1999, 39:123-129
17. Guo Y, Higazi A, Arakelian A, Sachais BS, Cines D, Goldfarb R, Jones T, Kwaan H, Mazar A, Rabbani SA: A peptide derived from the nonreceptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivo. EMBO J 2000, 14:1400-1410
18. Mishima K, Mazar A, Gown A, Skelly M, Ji, X-D, Wang, X-D, Jones TR, Cavenee WK, Huang H-J: A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin. Proc Natl Acad Sci USA 2000, 97:8484-8489
19. Pettaway CA, Pathak S, Greene G, Ramirez E, Wilson MR, Killion JJ, Fidler IJ: Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice. Clin Cancer Res 1996, 2:1627-1636
20. Allgayer H, Wang H, Gallick GE, Crabtree A, Mazar A, Jones T. Kraker AJ, Boyd DD: Transcriptional induction of the urokinase receptor gene by a constitutively active Src. Requirement of an upstream motif (-152/-135) bound with Sp1. J Biol Chem 1999, 274:18428-18445
21. Hollas W, Blasi F, Boyd D: Role of the urokinase receptor in facilitating extracellular matrix invasion by cultured colon cancer. Cancer Res 1991, 51:3690-3695
22. Popesko P, Rajtova V, Horak, J: A Color Atlas of Anatomy of Small Laboratory Animals. Volume II: Rat, Mouse, Hamster. London, Wolfe Publishing Ltd., 1992, pp 157-159
23. Vassalli, J-D, Belin D: Amiloride selectively inhibits the urokinase-type plasminogen activator. FEBS Lett 1987, 214:187-191
24. Wang Y, Dang J, Liang X, Doe WF: Amiloride modulates urokinase gene expression at both transcription and post-transcription levels in human colon cancer cells. Clin Exp Metast 1995, 13:196-202
25. Wang Y, Jones CJ, Dang J, Liang X, Olsen JE, Doe WF: Human urokinase receptor expression is inhibited by amiloride an induced by tumor necrosis factor and phorbol ester in colon cancer cells. FEBS Lett 1994, 353:138-142
26. Guo Y, Mazar A, Lebrun J, Rabbani SA: An antiangiogenic urokinase-derived peptide combined with tamoxifen decreases tumor growth and metastasis in a syngeneic model of breast cancer. Cancer Res 2002, 62:4678-4684
27. Rabbani SA, Harakidas P, Bowlin T, Attardo G: Effect of nucleoside analogue BCH-4556 on prostate cancer growth and metastases in vitro and in vivo. Cancer Res 1998, 58:3461-3465
28. Wei Y, Yang X, Liu Q, Wilkins JA, Chapman HA: A role for caveolin and the urokinase receptor in integrin-mediated adhesion and signaling. J Cell Biol 1999, 144:1285-1294
29. Ghiso JA, Kovalski K, Ossowski L: Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J Cell Biol 1999, 147:89-103
30. Aguirre-Ghiso JA, Liu D, Mignatti A, Kovalski K, Ossowski L: Urokinase receptor and fibronectin regulate the ERK to p38 activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Mol Biol Cell 2001, 12:863-879
31. Min HY, Doyle LV, Vitt CR, Zandonella CL, Stratton-Thomas JR, Shuman MA, Rosenberg S: Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res 1996, 56:2428-2433
32. Goodson RJ, Doyle MY, Kaufman SE, Rosenberg S: High-affinity urokinase receptor antagonists identified with bacteriophage peptide display. Proc Natl Acad Sci USA 1994, 91:7129-7133
33. Jankun J, Keck RW, Skzypczak-Jankun E, Swiercz R: Inhibitors of urokinase reduce size of prostate cancer xenografts in severe combined immunodeficient mice. Cancer Res 1997, 57:559-563
34. Franco P, Iaccarino C, Chiaradonna F, Frandazza A, Iavarone C, Mastronicola MR, Nolli ML, Stoppelli MP: Phosphorylation of human pro-urokinase on Ser 138/303 impairs its receptor-dependent ability to promote myelomonocytic adherence and motility. J Cell Biol 1997, 137:779-791